Cancer Research and Treatment

Original Articles

Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study: Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn, Youn Wha Kim, Seung-Mo Hong, on behalf of the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists; Cancer Res Treat. 2020;52(1):263-276. Published online July 12, 2019; DOI: https://doi.org/10.4143/crt.2019.192

Abstract PDF Supplementary Material PubReader ePub

Purpose
The most recent 2017 World Health Organization (WHO) classification of pancreatic neuroendocrine neoplasms (PanNENs) has refined the three-tiered 2010 scheme by separating grade 3 pancreatic neuroendocrine tumors (G3 PanNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs). However, differentiating between G3 Pan- NETs and PanNECs is difficult in clinical practice.
Materials and Methods
Eighty-two surgically resected PanNENs were collected from 16 institutions and reclassified according to the 2017 WHO classification based on the histological features and proliferation index (mitosis and Ki-67). Immunohistochemical stains for ATRX, DAXX, retinoblastoma, p53, Smad4, p16, and MUC1 were performed for 15 high-grade PanNENs.
Results
Re-classification resulted in 20 G1 PanNETs (24%), 47 G2 PanNETs (57%), eight G3 well-differentiated PanNETs (10%), and seven poorly differentiated PanNECs (9%). PanNECs showed more frequent diffuse nuclear atypia, solid growth patterns and apoptosis, less frequent organoid growth and regular vascular patterns, and absence of low-grade PanNET components than PanNETs. The Ki-67 index was significantly higher in PanNEC (58.2%± 15.1%) compared to G3 PanNET (22.6%±6.1%, p < 0.001). Abnormal expression of any two of p53, p16, MUC1, and Smad4 could discriminate PanNECs from G3 PanNETs with 100% specificity and 87.5% sensitivity.
Conclusion
Histological features supporting the diagnosis of PanNECs over G3 PanNETs were the absence of a low-grade PanNET component in the tumor, the presence of diffuse marked nuclear atypia, solid growth pattern, frequent apoptosis and markedly increased proliferative activity with homogeneous Ki-67 labeling. Immunohistochemical stains for p53, p16, MUC1, and Smad4 may be helpful in distinguishing PanNECs from G3 PanNETs in histologically ambiguous cases, especially in diagnostic practice when only small biopsied tissues are available.

Citations

Citations to this article as recorded by

Treatment status, survival and gene expression analysis of large-cell neuroendocrine lung carcinoma: a real-world study in China
Fei Qi, Minghang Zhang, Yi Han, Juan Du, Hongjie Yang, Hongmei Zhang, Yong Zhang, Tongmei Zhang
Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis
Matteo Tacelli, Manuel Gentiluomo, Paolo Biamonte, Justo P. Castano, Maja Cigrovski Berković, Mauro Cives, Sanja Kapitanović, Ilaria Marinoni, Sonja Marinovic, Ilias Nikas, Lenka Nosáková, Sergio Pedraza-Arevalo, Eleonora Pellè, Aurel Perren, Jonathan Str
Seminars in Cancer Biology.2025; 112: 112. CrossRef
Malignant potential of neuroendocrine microtumor of the pancreas harboring high-grade transformation: lesson learned from a patient with von Hippel-Lindau syndrome
Jongwon Lee, Kyung Jin Lee, Dae Wook Hwang, Seung-Mo Hong
Journal of Pathology and Translational Medicine.2024; 58(2): 91. CrossRef
Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation
Atsuko Kasajima, Nicole Pfarr, Eva-Maria Mayr, Ayako Ura, Elisa Moser, Alexander von Werder, Abbas Agaimy, Marianne Pavel, Günter Klöppel
Endocrine Pathology.2024; 35(4): 313. CrossRef
The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors—An Overview of the Latest Classifications
Ancuța-Augustina Gheorghișan-Gălățeanu, Andreea Ilieșiu, Ioana Maria Lambrescu, Dana Antonia Țăpoi
International Journal of Molecular Sciences.2023; 24(2): 1418. CrossRef
All Together Now
Pari Jafari, Aliya N. Husain, Namrata Setia
Surgical Pathology Clinics.2023; 16(1): 131. CrossRef
A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
Mauro D. Donadio, Ângelo B. Brito, Rachel P. Riechelmann
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus
Tomoyuki Okumura, Tsutomu Fujii, Kenji Terabayashi, Takashi Kojima, Shigeru Takeda, Tomomi Kashiwada, Kazuhiro Toriyama, Susumu Hijioka, Tatsuya Miyazaki, Miho Yamamoto, Shunsuke Tanabe, Yasuhiro Shirakawa, Masayuki Furukawa, Yoshitaka Honma, Isamu Hoshin
Oncology Letters.2023;[Epub] CrossRef
The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%)
Yongkang Liu, Jiangchuan Wang, Hao Zhou, Zicheng Wei, Jianhua Wang, Zhongqiu Wang, Xiao Chen
BMC Gastroenterology.2023;[Epub] CrossRef
An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features
Atsuko Kasajima, Björn Konukiewitz, Anna Melissa Schlitter, Wilko Weichert, Günter Klöppel
Virchows Archiv.2022; 480(2): 359. CrossRef
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms
Tiago Bordeira Gaspar, José Manuel Lopes, Paula Soares, João Vinagre
Endocrine-Related Cancer.2022; 29(12): R191. CrossRef
Solid pancreatic masses in children: A review of current evidence and clinical challenges
Kelli N. Patterson, Andrew T. Trout, Archana Shenoy, Maisam Abu-El-Haija, Jaimie D. Nathan
Frontiers in Pediatrics.2022;[Epub] CrossRef
Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review
Tiziana Feola, Roberta Centello, Franz Sesti, Giulia Puliani, Monica Verrico, Valentina Di Vito, Cira Di Gioia, Oreste Bagni, Andrea Lenzi, Andrea M. Isidori, Elisa Giannetta, Antongiulio Faggiano
Cancers.2021; 13(6): 1247. CrossRef
Risk of cancer in patients with recurrent aphthous stomatitis in Korea
Ki Jin Kwon, Su Jin Jeong, Young-Gyu Eun, In Hwan Oh, Young Chan Lee
Medicine.2021; 100(16): e25628. CrossRef
Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions
Anna Pellat, Anne Ségolène Cottereau, Lola-Jade Palmieri, Philippe Soyer, Ugo Marchese, Catherine Brezault, Romain Coriat
Cancers.2021; 13(10): 2448. CrossRef
Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
Anna Pellat, Anne Ségolène Cottereau, Benoit Terris, Romain Coriat
Cancers.2021; 13(15): 3766. CrossRef
Pancreatic Masses in Children and Young Adults: Multimodality Review with Pathologic Correlation
Lisa Qiu, Andrew T. Trout, Rama S. Ayyala, Sara Szabo, Jaimie D. Nathan, James I. Geller, Jonathan R. Dillman
RadioGraphics.2021; 41(6): 1766. CrossRef
CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms

Xin Chen, Chuangen Guo, Wenjing Cui, Ke Sun, Zhongqiu Wang, Xiao Chen
Cancer Management and Research.2020; Volume 12: 4625. CrossRef
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
Lingaku Lee, Tetsuhide Ito, Robert T Jensen
Expert Review of Anticancer Therapy.2019; 19(12): 1029. CrossRef

10,794 View
320 Download
17 Web of Science
19 Crossref

Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma: Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang; Cancer Res Treat. 2019;51(1):24-33. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2017.404

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the impact of contrast enhanced pancreatic magnetic resonance imaging (MRI) in resectability and prognosis evaluation after staging computed tomography (CT) in patients with pancreatic ductal adenocarcinoma (PDA).
Materials and Methods
From January 2005 to December 2012, 298 patients were diagnosed to have potentially resectable stage PDA on CT. Patients were divided into CT+MR (patients underwent both CT and MRI; n=216) and CT only groups (n=82). Changes in resectability staging in the CT+MR group were evaluated. The overall survival was compared between the two groups. The recurrence-free survival and median time to liver metastasis after curative surgery were compared between the two groups.
Results
Staging was changed from resectable on CT to unresectable state on MRI in 14.4% of (31 of 216 patients) patients of the CT+MR group. The overall survival and recurrence-free survival rates were not significantly different between the two groups (p=0.162 and p=0.721, respectively). The median time to liver metastases after curative surgery in the CT+MR group (9.9 months) was significantly longer than that in the CT group (4.2 months) (p=0.011).
Conclusion
Additional MRI resulted in changes of resectability and treatment modifications in a significant proportion of patients who have potentially resectable state at CT and in prolonged time to liver metastases in patients after curative surgery. Additional MRI to standard staging CT can be recommended for surgical candidates of PDA.

Citations

Citations to this article as recorded by

Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Doaa Bugazia, Ebtesam Al-Najjar, Abdullah Esmail, Saifudeen Abdelrahim, Karen Abboud, Adham Abdelrahim, Godsfavour Umoru, Hashem A. Rayyan, Ala Abudayyeh, Ala-Eddin Al Moustafa, Maen Abdelrahim
Frontiers in Oncology.2024;[Epub] CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2024; 62(10): e874. CrossRef
S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1
Thomas Seufferlein, Julia Mayerle, Stefan Boeck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2024; 62(10): 1724. CrossRef
Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
Felix G. Gassert, Sebastian Ziegelmayer, Johanna Luitjens, Florian T. Gassert, Fabian Tollens, Johann Rink, Marcus R. Makowski, Johannes Rübenthaler, Matthias F. Froelich
European Radiology.2022; 32(4): 2448. CrossRef
Diagnostik beim Pankreaskarzinom – Update in der neuen Leitlinie
L. Grenacher, M. Juchems, A. G. Schreyer, J. Wessling, K. I. Ringe, W. Uhl, J. Mayerle, T. Seufferlein
Der Chirurg.2022; 93(5): 429. CrossRef
Pancreatic adenocarcinoma: imaging techniques for diagnosis and management
Jawaad Farrukh, Ravivarma Balasubramaniam, Anitha James, Sharan S Wadhwani, Raneem Albazaz
British Journal of Hospital Medicine.2022; 83(5): 1. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL
Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2022; 60(06): 991. CrossRef
S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL
Thomas Seufferlein, Julia Mayerle, Stefan Böck, Thomas Brunner, Thomas J. Ettrich, Lars Grenacher, Thomas Mathias Gress, Thilo Hackert, Volker Heinemann, Angelika Kestler, Marianne Sinn, Andrea Tannapfel, Ulrich Wedding, Waldemar Uhl
Zeitschrift für Gastroenterologie.2022; 60(11): e812. CrossRef
The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
Hyungjin Rhee, Mi-Suk Park
Korean Journal of Radiology.2021; 22(1): 23. CrossRef
A Comparative Study of Survivor Outcomes between Preoperative Evaluation Using CT Alone and Combined CT and MRI in Patients with Pancreatic Ductal Adenocarcinoma
Ji Eun Lee, Seong Hyun Kim, Soon Jin Lee, Seo-Youn Choi, Sunyoung Lee, Bo Ra Lee
Journal of the Korean Society of Radiology.2021; 82(3): 638. CrossRef
СT and MRI in the assessment of resectable and borderline resectable pancreatic tumors
A. V. Kudryavtseva, S. S. Bagnenko, I. I. Dzidzawa, I. S. Zheleznyak, G. E. Trufanov, V. V. Ryazanov, V. A. Krasovskaya, A. B. Kotiv, A. D. Kazakov
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2021; 26(1): 34. CrossRef
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graça Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferollà, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet
Cancer Treatment Reviews.2021; 99: 102208. CrossRef
ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial
Ken-ichi Okada, Manabu Kawai, Seiko Hirono, Masayuki Sho, Masaji Tani, Ippei Matsumoto, Suguru Yamada, Ryosuke Amano, Hirochika Toyama, Yo-ichi Yamashita, Takeshi Gocho, Kazuto Shibuya, Minako Nagai, Hiromitsu Maehira, Keiko Kamei, Go Ohira, Yoshihiro Shi
Trials.2021;[Epub] CrossRef
Management of Primary Squamous Cell Carcinoma of the Pancreas: A Case Report
Danling Guo, Chao Chen, Sangying Lv, Guanzuan Wu, Wei Shi, Huaifeng Li, Hongjie Hu
Frontiers in Surgery.2021;[Epub] CrossRef
Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC
Min Woo Kim, Hani Koh, Jee Ye Kim, Suji Lee, Hyojung Lee, Young Kim, Ho Kyoung Hwang, Seung Il Kim
International Journal of Molecular Sciences.2021; 22(24): 13621. CrossRef
Imaging and Management of Pancreatic Cancer
Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
Seminars in Ultrasound, CT and MRI.2020; 41(2): 139. CrossRef
DUPLICATE: Imaging and Management of Pancreatic Cancer
Mariya Kobi, Gregory Veillette, Roshni Narurkar, David Sadowsky, Viktoriya Paroder, Chaitanya Shilagani, Anthony Gilet, Milana Flusberg
Seminars in Ultrasound, CT and MRI.2019;[Epub] CrossRef

11,024 View
319 Download
18 Web of Science
17 Crossref

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only: Su-Jin Shin, Hosub Park, You-Na Sung, Changhoon Yoo, Dae Wook Hwang, Jin-hong Park, Kyu-pyo Kim, Sang Soo Lee, Baek-Yeol Ryoo, Dong-Wan Seo, Song Cheol Kim, Seung-Mo Hong; Cancer Res Treat. 2018;50(4):1175-1185. Published online December 20, 2017; DOI: https://doi.org/10.4143/crt.2017.494

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pancreatic cancer associated double primary tumors are rare and their clinicopathologic characteristics are not well elucidated.
Materials and Methods
Clinicopathologic factors of 1,352 primary pancreatic cancers with or without associated double primary tumors were evaluated.
Results
Of resected primary pancreatic cancers, 113 (8.4%) had associated double primary tumors, including 26 stomach, 25 colorectal, 18 lung, and 13 thyroid cancers. The median interval between the diagnoses of pancreatic cancer and associated double primary tumors was 0.5 months. Overall survival (OS) of pancreatic cancer patients with associated double primary tumors was longer than those with pancreatic cancer only (median, 23.1 months vs. 17.0 months, p=0.002). Patients whose pancreatic cancers were resected before the diagnosis of metachronous tumors had a better OS than patients whose pancreatic cancer resected after the diagnosis of metachronous tumors (48.9 months and 13.5 months, p=0.001) or those whose pancreatic cancers were resected synchronously with non-pancreas tumors (19.1 months, p=0.043). The OS of pancreatic cancer patients with stomach (33.9 months, p=0.032) and thyroid (117.8 months, p=0.049) cancers was significantly better than those with pancreas cancer only (17.0 months).
Conclusion
About 8% of resected pancreatic cancers had associated double primary tumors, and those from the colorectum, stomach, lung, and thyroid were common. Patients whose pancreatic cancer was resected before the diagnosis of metachronous tumors had better OS than those resected after the diagnosis of metachronous tumors or those resected synchronously.

Citations

Citations to this article as recorded by

Laparoscopic Radical Total Gastrectomy and Pancreatosplenectomy for Synchronous Cancer of the Stomach and Pancreas
Motoki Ebihara, Kentoku Fujisawa, Shusuke Haruta, Hironori Uruga, Masaki Ueno
Cureus.2024;[Epub] CrossRef
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail
G.R. Setdikova, E.A. Stepanova, A.N. Verbovsky, A.V. Semenkov
Pirogov Russian Journal of Surgery.2024; (8): 57. CrossRef
Pancreatoduodenectomy after Ivor-Lewis Santi oesophagectomy with gastric tube reconstruction. An European multicentre experience
Alessandro D. Mazzotta, Pietro Addeo, Benedetto Ielpo, Michael Ginesini, Nicolas Regenet, Ugo Boggi, Philippe Bachellier, Olivier Soubrane
Surgical Oncology.2024; 57: 102144. CrossRef
The importance of hsa-miR-28 in human malignancies
Seyede Fatemeh Hosseini, Setareh Javanshir-giv, Hanieh Soleimani, Homa Mollaei, Farzad Sadri, Zohreh Rezaei
Biomedicine & Pharmacotherapy.2023; 161: 114453. CrossRef
Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
Takahiro Murokawa, Takehiro Okabayashi, Kenta Sui, Motoyasu Tabuchi, Jun Iwata
Surgical Case Reports.2022;[Epub] CrossRef
A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience
Moustafa S. Alhamadh, Rakan B. Alanazi, Sultan T. Algarni, Ahmed Abdullah R. Alhuntushi, Mohammed Qasim Alshehri, Yusra Sajid Chachar, Mohammad Alkaiyat, Fouad Sabatin
Current Oncology.2022; 29(7): 4941. CrossRef
Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review
Daniel Paramythiotis, Georgia Fotiadou, Eleni Karlafti, Ioanna Abba Deka, Georgios Petrakis, Elisavet Psoma, Xanthippi Mavropoulou, Filippos Kyriakidis, Smaro Netta, Stylianos Apostolidis
Diagnostics.2022; 12(11): 2709. CrossRef
Ergebnisse nach Pankreaseingriffen aus Sicht der Betroffenen: Versorgungsforschung der Selbsthilfegruppe „Arbeitskreis der Pankreatektomierten e. V.“
Ioannis Dimopoulos, Gabriele Meyer, Saleem Ibrahim Elhabash, Michele Sorleto, Carsten Gartung, Nils Ewald, Ulrich Klaus Fetzner, Lutz Otto, Friedhelm Möhlenbrock, Waldemar Uhl, Berthold Gerdes
Zeitschrift für Gastroenterologie.2021; 59(03): 214. CrossRef
An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases
Lei Zhang, Xin Long, Zheng-Nan Hu, Yu Wu, Jia Song, Bi-Xiang Zhang, Wei-Xun Chen
Medicine.2021; 100(20): e25785. CrossRef
Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis
Hironori Hayashi, Koji Amaya, Tomokazu Tokoro, Kosuke Mori, Shunsuke Takenaka, Yuya Sugimoto, Yuto Kitano, Toru Kurata, Shunsuke Kawai, Atsushi Hirose, Tomoya Tsukada, Masahide Kaji, Koichi Shimizu, Kiichi Maeda
Molecular and Clinical Oncology.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature
Tian Fang, Ting-Ting Liang, Yi-Zhuo Wang, Hai-Tao Wu, Shu-Han Liu, Chang Wang
World Journal of Clinical Cases.2021; 9(28): 8509. CrossRef
A novel long non‑coding RNA TTN‑AS1/microRNA‑589‑5p/FOXP1 positive feedback loop increases the proliferation, migration and invasion of pancreatic cancer cell lines
Jing Zhao, Fang Wu, Jun Yang
Oncology Letters.2021;[Epub] CrossRef
Multiple primary gastrointestinal tumors of gastric, pancreatic and rectal origin; a case report
Abdullah Mohammed Aloraini, Hadeel Ayman Helmi, Nadia Abdulaziz Aljomah, Ahmad Mohmmed Zubaidi
International Journal of Surgery Case Reports.2021; 89: 106610. CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression
Qing Han, Junhe Li, Jianping Xiong, Zhiwang Song
Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef
Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
Oronzo Brunetti, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia Maria Soccorsa Perrotti, Rosamaria Pinto, Daniela Petriella, Katia Danza, Stefania Tommasi, Francesco Leonetti,
Cancers.2019; 11(6): 749. CrossRef

14,776 View
246 Download
17 Web of Science
17 Crossref

Case Reports

Multiple Cardiac Metastases from a Nonfunctioning Pancreatic Neuroendocrine Tumor: Yong Hyeok Choi, Hye-Suk Han, Sung-Nam Lim, Sang Yeub Lee, Ji Hae Koo, Ok-Jun Lee, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2013;45(2):150-154. Published online June 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.2.150

Abstract PDF PubReader ePub

Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms, which most commonly metastasize to the liver. However, intrathoracic metastases from pNETs are encountered infrequently. This report describes a case of nonfunctioning pNET with multiple cardiac metastases. A 56-year-old male presented with a palpable abdominal mass that showed progressive enlargement. Findings on computed tomography (CT) of the abdomen revealed two relatively well-marginated inhomogeneous low-attenuation masses, one in the head of the pancreas and the other in the tail. Multiple enhancing masses in the left pericardium with myocardial involvement were observed on chest CT and transthoracic echocardiography. Needle biopsies were performed on the mass in the tail of the pancreas and the left ventricular apical pericardium; histologic examination by hematoxylin and eosin morphology and immunohistochemical staining showed pNET in both. This is the first report of pNET with multiple cardiac metastases to previously undescribed metastatic sites.

Citations

Citations to this article as recorded by

Cardiac Neuroendocrine Tumor Metastases on68Ga-DOTATATE PET/CT: Identification and Prognostic Significance
Hwan Lee, Ahmad S. Alhamshari, Vandan Patel, Abhijit Bhattaru, Chaitanya Rojulpote, Mahesh K. Vidula, Daniel A. Pryma, Paco E. Bravo
Journal of Nuclear Medicine.2024; 65(11): 1745. CrossRef
Atypical Cardiac Location of Melanoma of Unknown Origin
Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Elżbieta Czekajska-Chehab, Andrzej Tomaszewski, Andrzej Wysokiński, Tomasz Zapolski
Medicina.2021; 57(2): 107. CrossRef
Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications
Man Liu, Eleni Armeni, Shaunak Navalkissoor, Joseph Davar, Luke Sullivan, Charlotte Leigh, Luke Furtado O’Mahony, Aimee Hayes, Dalvinder Mandair, Jie Chen, Martyn Caplin, Christos Toumpanakis
Neuroendocrinology.2021; 111(10): 907. CrossRef
A concealed carcinoid cardiac metastasis uncovered by comprehensive cardiovascular magnetic resonance-based tissue characterization: a case report
Georgios Georgiopoulos, Panagiota Mitropoulou, Pier Giorgio Masci, Juerg Schwitter, Khan Tina, Voges Inga, Raisi Estabragh Zahra, Minguito Carazo Carlos, Thomson Ross
European Heart Journal - Case Reports.2020; 4(6): 1. CrossRef
A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer
Nadeem Bilani, Leah Elson, Felipe Martinez, Diego Sadler, Zeina Nahleh, Elizabeth Elimimian, Evan Alley
Case Reports in Oncology.2020; 13(1): 212. CrossRef
Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT
Shengming Deng, Bin Zhang, Jihui Li, Shibiao Sang, Wei Zhang
Medicine.2018; 97(49): e12868. CrossRef

12,426 View
67 Download
6 Crossref

Clear Cell Carcinoma of the Pancreas -A Case Report and Review of the Literature-: Hui-Young Lee, Dong-Gyu Lee, Kwangjin Chun, Seungkoo Lee, Seo-Young Song; Cancer Res Treat. 2009;41(3):175-181. Published online September 29, 2009; DOI: https://doi.org/10.4143/crt.2009.41.3.175

Abstract PDF PubReader ePub

Most of the malignant neoplasms of the pancreas demonstrate features that are consistent with adenocarcinoma. According to the WHO classification, primary clear cell carcinoma of the pancreas is rare and it is classified as a "miscellaneous" carcinoma. In addition, there is not an adequate systematic overview that can demonstrate its true existence as a definable entity. We report here on an unusual case of primary pancreatic clear cell carcinoma, which is the first such reported case in Korea. A 66 year old woman presented with abdominal pain and significant weight loss over the previous three weeks. On the abdominal computed tomography (CT), we detected an abdominal mass involving the pancreas tail and liver, and clear cell carcinoma with rhabdoid feature was seen on the histologic evaluation. The tumor cells showed well defined cell membranes, clear cytoplasm and prominent cell boundaries. The immunohistochemical stains showed positive reactions to antibodies against pan-cytokeratin, cytokeratin 7, carcinoembryonic antigen (CEA) and epithelial membrane antigen (EMA). On the other hand, there was a negative reaction for cytokeratin 20, chromogranin, synaptophysin, smooth muscle actin and HMB-45. She was diagnosed with a primary pancreatic clear cell carcinoma with hepatic metastasis and she received palliative gemcitabine chemotherapy. The patient died one month later of pancreatic cancer progression.

Citations

Citations to this article as recorded by

Metastatic clear cell sarcoma of the pancreas: An overview
Rachid Ait Addi
World Journal of Clinical Cases.2024; 12(29): 6262. CrossRef
Long-Term Survival After Curative Resection of a Primary Clear Cell Carcinoma of the Pancreas: A Report of a Case
Helen Bolanaki, Christina Nikolaou, George Pappas Gogos, Anastasios J Karayiannakis
Cureus.2024;[Epub] CrossRef
Primary Clear Cell Carcinoma of the Pancreas: A Rare Case Report
Yoo-Na Kang
Diagnostics.2022; 12(9): 2046. CrossRef
Primary Clear Cell Carcinoma of the Pancreas: A Systematic Review
Toufic Tannous, Audrik L Perez Rodriguez, Andrew W Mak, Karim Tannous, Matthew Keating
Cureus.2021;[Epub] CrossRef
Two Cases of Rare Pancreatic Malignancies
Wissam Hanayneh, Hiral Parekh, Garrett Fitzpatrick, Michael Feely, Thomas J. George, Jason S. Starr
Journal of Pancreatic Cancer.2019; 5(1): 26. CrossRef
Primary signet ring cell carcinoma of the pancreas: Cytopathology review of a rare entity
Siba El Hussein, Samer N. Khader
Diagnostic Cytopathology.2019; 47(12): 1314. CrossRef
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors
Oronzo Brunetti, Giuseppe Aprile, Paolo Marchetti, Enrico Vasile, Andrea Casadei Gardini, Mario Scartozzi, Sandro Barni, Sara Delfanti, Fernando De Vita, Francesco Di Costanzo, Michele Milella, Chiara Alessandra Cella, Rossana Berardi, Ivana Cataldo, Aldo
Pancreas.2018; 47(6): 759. CrossRef
Hyalinizing clear cell carcinoma arising in the lower with cervical lymph node metastasis: Report of a case and review of literature
Aya Hamao-Sakamoto, Jason Mull, Patrick Wang, John Randall Zuniga
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2014; 26(4): 585. CrossRef
Canine Pancreatic Clear Acinar Cell Carcinoma Showing an Unusual Mucinous Differentiation
S. Pavone, E. Manuali, C. Eleni, A. Ferrari, E. Bonanno, A. Ciorba
Journal of Comparative Pathology.2011; 145(4): 355. CrossRef

8,929 View
74 Download
9 Crossref

A Case of Recurrent Solid Pseudopapillary Tumor of the Pancreas with Involvement of the Spleen and Kidney: Sang Eun Park, Nam Sook Park, Jae Min Chun, Nam Whan Park, Young Joon Yang, Gak Won Yun, Hyo Jin Lee, Hwan Jung Yun, Deog Yeon Jo, Kyu Sang Song, Samyong Kim; Cancer Res Treat. 2006;38(2):118-120. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.118

Abstract PDF PubReader ePub

Solid pseudopapillary tumor of the pancreas (SPTP) is a rare primary pancreatic tumor of an unknown etiology that is usually diagnosed in adolescent girls and young women. Most SPTPs are considered to be benign and only rarely metastasize. We report here on a 27-year old woman with recurrent SPTP with involvement of both the spleen and left kidney at the time of the initial diagnosis, and with aggressive behavior. In July 1995, she was admitted with abdominal discomfort and mass. She underwent exploratory laparotomy with distal pancrea tectomy, left nephrectomy and splenectomy, and was diagnosed with SPTP with invasion to both the spleen and left kidney. In June 2001, she again presented with abdominal pain and was diagnosed as having recurrence of the tumor. She underwent mass excision and omentectomy. Then she was lost to follow-up. In November 2005, she presented once again with an abdominal mass and was diagnosed with recurred SPTP, which formed a huge intraperitoneal mass with peritoneal seeding and the tumor showed multiple metastases in the liver. She is currently being treated conservatively.

Citations

Citations to this article as recorded by

Clinical Pattern of Preoperative Positron Emission Tomography/Computed Tomography (PET/CT) Can Predict the Aggressive Behavior of Resected Solid Pseudopapillary Neoplasm of the Pancreas
Ji-Su Kim, Emmanuel II-Uy Hao, Seoung-Yoon Rho, Ho-Kyoung Hwang, Woo-Jung Lee, Dong-Sub Yoon, Chang-Moo Kang
Cancers.2021; 13(9): 2119. CrossRef

8,312 View
42 Download
1 Crossref

Original Articles

Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study: Jung Hye Choi, Myung Ju Ahn, Seock Ah Im, Bong Seog Kim, Ho Suk Oh, Heung Woo Lee, Yeung Chul Mun, Chu Myung Seong, Soon Nam Lee, Young Yeul Lee, Il Young Choi, In Soon Kim; Cancer Res Treat. 2003;35(3):213-217. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.213

Abstract PDF: PURPOSE
Gemcitabine and 5-fluorouracil (5-FU) are two compounds with reproducible activity against advanced pancreatic carcinomas. To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty patients (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic pancreatic carcinomas, were enrolled between April 2000 and March 2002. Gemcitabine was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and 5-FU 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the pain, Karnofsky performance status and body weight change measurement.
RESULTS
Nineteen of the twenty patients were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five patients achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 patients. The overall CBR was 41.7% (5/12). The median survival of all the patients was 8.0 months. Grade 3~4 toxicities included neutropenia (9.3%) and thrombocytopenia (5.3%). CONCLUSION: This study suggested that gemcitabine, combined with infusional 5-FU, was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced pancreatic cancer patients.

3,862 View
32 Download

Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma: So Young Yoon, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Jae Seon Kim, Chang Duck Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2002;34(2):111-116. Published online April 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.2.111

Abstract PDF

PURPOSE
To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients <=70 years, with no prior chemotherapy and with bidimensionally measurable advanced pancreatic adenocarcinoma, ECOG performance status <=2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or a Karnofsky performance status between 50 and 70. Treatment consisted of 1,000 mg/m2 of Gemcitabine on days 1, 8 and 15, repeated every 4 weeks, with UFT-E administered orally 500 mg-700 mg by body surface area (BSA). Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were divided and administered three times per day from day 1 to day 21. After 7 days of rest, UFT-E and Leucovorin were administered repeatedly.
RESULTS
Twenty-three patients were enrolled between April 1999 to April 2000. Eighty two cycles (median, four cycles) were delivered to all patients. The objective response rate was 15.8% in 19 assessable patients and 13.0% in the intent-to-treat population. Twelve patients (57.9%) displayed stable disease. Grade 3 or 4 neutropenia occurred in 30.4% of patients, nausea/vomiting in 8.3%, diarrhea in 4.3%, and mucositis in 4.3%. The median time to progression was 8 months. The median survival was 8 months in the assessable population and 6 months in the intent-to-treat population Clinical benefit was achieved in 11 (57.9%) of 19 assessable patients.
CONCLUSION
Gemcitabine, UFT-E, Leucovorin combination chemotherapy is a well-tolerated and safe regimen in cases of advanced pancreatic adenocarcinoma. Although the response rate is low, it shows a survival benefit and clinical benefit and deserves further evaluation in a phase III trial.

Citations

Citations to this article as recorded by

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim
Cancer Chemotherapy and Pharmacology.2009; 64(2): 317. CrossRef

4,665 View
18 Download
1 Crossref

Pediatric Pancreatic Tumors: Dae Yeon Kim, Min Gew Choi, Ki Hong Kim, In One Kim, Sung Eun Jung, Seong Cheol Lee, Kwi Won Park, Woo Ki Kim; J Korean Cancer Assoc. 1999;31(4):830-835.

Abstract PDF: PURPOSE
Pancreatic tumors are relatively rare in children. Until now more than 150 cases have been reported in the English literature. In this paper, the authors report the tumors clinical characteristics and the results of surgery in eleven children.
MATERIALS AND METHODS
Eleven cases of pancreatic tumor pathologically verified at Seoul National University Children's Hospital between 1984 to 1998 were retrospectively analyzed. Four were boys and seven were girls, and their mean age at diagnosis was 7.7 (range, 2 13) years.
RESULTS
There were six solid and papillary epithelial neoplasms of the pancreas (SPENP) and five pancreatoblastomas. All children came to medical attention because of abdominal masses. Tumors ranged in size from 6.0X 5.0 cm to 10.5 x 8.0 cm. Eight tumors were located in head and three in tail. Complete excision was performed in eight cases (six in SPENP and two in pancreatoblastoma). Incomplete excision was performed in two cases of pancreatoblastoma. One patient with pancreatoblastoma had an unresectable tumor at the time of diagnosis and needle aspiration biopsy was done under the ultrasound guidance. No patient died during surgery. After a mean follow-up period of 4.1 years, all patients with SPENP were alive and there had been no recurrence. However, of two patients who received complete excision in pancreatoblastoma, one presented with liver metastasis at 4 months after operation and received chemotherapy, but died 6 months after operation. The other patient had local recurrence 1 year after operation. Reoperation and chemotherapy were performed and the child is now alive without evidence of disease montbs after the initial operation. All three patients with unresectable tumor died in spite of adjuvant radiotherapy and chemotherapy.
CONCLUSION
Pediatric pancreatic tumors comprise rare heterogenous groups of malignancies with their prognosis dependent upon adequate resection and pathologic classification. Complete resection of pancreatic tumors arising anywhere in the pancreas was recommended.

2,765 View
17 Download

Metastatic Papillary Cystic Neoplasm of Pancreas in Child - Report of a case -: Seung Tae Han, Kyung Rae Kim, Yong Hwa Moon, Young Chae Chu, Chuhl Joo Lyu, Byung Soo Kim; J Korean Cancer Assoc. 1990;22(3):600-607.

Abstract PDF: Papillary cystic neoplasm of the pancreas is rare low grade malignant tumor, especially in children, and that occurs chiefly in young women. This type of pancreatic tumor has more benign clinical features than any other type of the tumor of the pancreas dose, and long survival or even cure can be expected by aggressive treatment. We present a 10-year-old frmle patient with a papillary-cystic neoplasm of the pancreas, she had distant metastatic evidences to the liver, omentum and peritoneum. The tumor was totally excised with the spleen and greater omentum, and chemotherapy was carried out with vincristine and 5-FU. On the follow up studies, there are neither evidence of recurrence nor evidence of disease and the child has been doing well for two years.

2,365 View
13 Download

Acinar Cell Carcinoma of the Pancreas - A case report -: Soo Young Chung, Ik Yang, Yul Lee, Hai Jung Park, Hye Kyung Ahn; J Korean Cancer Assoc. 1995;27(4):692-696.

Abstract PDF: Acinar cell carcinoma in pancreas is uncommon and occurs in less than 2% among the epithelial non-endocrine pancreatic tumors. Acinar cell carcinoma is usually seen in the elderly patients and shows poor prognosis due to frequent metastasis. A 59 year old man was admitted because of indigestion and abdominal distension. A large, irregular, marginated, heterogeneous and hypodense mass with internal necrosis in pancreas was the characteristic CT feature of acinar cell carcinoma in pancreas. Celiac arteriogram showed a central hypovascular mass with sweeping of left gastric artery. Superic; mesenteric arteriography showed tortuous neovascularity along the peripheral portion of mass. Gross specimen showed an ill defined ovoid pink friable mass with a portion of necrotic yellow area. Light microscope showed gyriform or glendular pattern devided by fine fibrovascular stroma. The cells have round vesicular nuclei with prominent nucleoli located in relatively basally and abundant cytoplasm. Multiple electron-dense cytoplasmic zymogen granules in cytoplasm of the enlarged acinar cells on electron microscope can lead the diagnosis. We report the CT and angiographic findings of a case of acinar cell carcinoma in pancreas.

2,972 View
21 Download

Acinar Cell Carcinoma in a Pancreas : Report of a recurrent case: Eun Sook Lee, Ki Hoon Jung, Nam Ryul Kim, Seon Hahn Kim, Sae Min Kim, Chul Hwan Kim; J Korean Cancer Assoc. 1996;28(4):782-787.

Abstract PDF: Acinar cell carcinoma of the pancreas is a rare neoplasm arising from the exocrine cells of the pancreas, comprising no more than 1 to 2% of all pancreatic cancers. CT appearence of pancreatic acinar carcinoma has been described as a sharply circumscribed mass with central necrosis. We report a case of recurrent acinar cell carcinoma of the pancreas in a 41-year-old man who had distal pancreatectomy three years ago for primary acinar cell carcinoma.

2,768 View
19 Download

First
Prev
Page of 1
Next
Last

Search